Morgan Stanley’s Apollo Global Management Series A APO.PRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.97M Sell
163,640
-446,844
-73% -$29M ﹤0.01% 3687
2026
Q1
$35.7M Buy
610,484
+505,724
+483% +$32.8M ﹤0.01% 2429
2025
Q4
$7.91M Sell
104,760
-21,331
-17% -$1.49M ﹤0.01% 3811
2025
Q3
$8.86M Buy
126,091
+34,486
+38% +$2.57M ﹤0.01% 3650
2025
Q2
$6.86M Sell
91,605
-45,017
-33% -$3.19M ﹤0.01% 3792
2025
Q1
$9.99M Buy
136,622
+94,300
+223% +$7.65M ﹤0.01% 3342
2024
Q4
$3.68M Sell
42,322
-202,432
-83% -$17M ﹤0.01% 4254
2024
Q3
$16.6M Buy
244,754
+153,277
+168% +$9.81M ﹤0.01% 2974
2024
Q2
$6M Sell
91,477
-51,685
-36% -$3.3M ﹤0.01% 3746
2024
Q1
$9.17M Buy
143,162
+110,041
+332% +$6.72M ﹤0.01% 3412
2023
Q4
$1.86M Sell
33,121
-116,458
-78% -$6.25M ﹤0.01% 4562
2023
Q3
$8.2M Buy
+149,579
New +$8.07M ﹤0.01% 3305

Other funds holding APO.PRA

Morgan Stanley's APO.PRA Position: Q2 2026 in Review

Morgan Stanley reduced its Apollo Global Management Series A (APO.PRA) stake by 73% in Q2 2026, selling an estimated $29M and leaving 163,640 shares worth $9.97M. The position accounts for ﹤0.01% of the portfolio, ranked #3687.

Morgan Stanley first reported a position in APO.PRA in Q3 2023 and has held it in 12 quarters since. The position peaked at $35.7M in Q1 2026. 66 funds tracked by Wall St. Rank hold APO.PRA as of Q2 2026.

  • Morgan Stanley held 163,640 shares of Apollo Global Management Series A worth $9.97M as of Q2 2026.
  • Morgan Stanley sold 446,844 Apollo Global Management Series A shares in Q2 2026, an estimated $29M.
  • Apollo Global Management Series A made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3687 holding.
  • Morgan Stanley first reported a position in Apollo Global Management Series A in Q3 2023 and has held it in 12 quarters since.
  • Morgan Stanley's Apollo Global Management Series A position peaked at $35.7M in Q1 2026.
  • 66 funds tracked by Wall St. Rank held Apollo Global Management Series A as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.